Update
$DiaMedica Therapeutics (DMAC.US)$ DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
2 MINUTES AGO, 8:27 AM EDT
VIA BUSINESSWIRE
• Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
2 MINUTES AGO, 8:27 AM EDT
VIA BUSINESSWIRE
• Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
